Table Info

Table 1.

Reasons for and against all people with gout receiving anti-inflammatory prophylaxis when initiating ULT

For	Against
ULT-induced flares are common and often lead ULT to be stopped	1 in 4 people with gout do not experience ULT-induced flares, even without prophylaxis
Prophylaxis reduces the incidence of ULT-induced flares, improving long-term adherence to ULT	‘Start low, go slow’ ULT leads to fewer ULT-induced flares than historical fixed dosing
Colchicine prophylaxis is cost-effective	Risk of adverse events
Potential CV benefits of colchicine	Drug interactions, polypharmacy
Difficulty predicting who is most at risk of ULT-induced flares	Difficulty predicting who is most at risk of adverse events
-	Financial burden of prescription costs to individuals
-	Some people may prefer the ‘pill in the pocket’ approach to treat flares than regular prophylaxis

-: no data. CKD: chronic kidney disease; CV: cardiovascular; ULT: urate-lowering therapy

Declarations

Author contributions

ER: Conceptualization, Writing—original draft, Writing—review & editing. JAP: Writing—review & editing. CDM: Conceptualization, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

CDM is director of the National Institute for Health and Care Research (NIHR) School for Primary Care Research. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72:744–60. [DOI] [PubMed] [PMC]

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29–42. [DOI] [PubMed]

Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al.; British Society for Rheumatology Standards; Audit and Guidelines Working Group. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017;56:1056–9. [DOI] [PubMed]

Neilson J, Bonnon A, Dickson A, Roddy E; Guideline Committee. Gout: diagnosis and management—summary of NICE guidance. BMJ. 2022;378:o1754. [DOI] [PubMed]

Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392:1403–12. [DOI] [PubMed] [PMC]

Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010;6:263–71. [DOI] [PubMed] [PMC]

Maher D, Reeve E, Hopkins A, Tan JM, Tantiongco M, Ailabouni N, et al. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis. Arthritis Care Res (Hoboken). 2024;76:871–81. [DOI] [PubMed]

Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429–32. [PubMed]

Stamp L, Horne A, Mihov B, Drake J, Haslett J, Chapman PT, et al. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Ann Rheum Dis. 2023;82:1626–34. [DOI] [PubMed]

10.

Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77:270–6. [DOI] [PubMed] [PMC]

11.

Templeton JS. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report. Br J Clin Pract. 1982;36:353–8. [DOI] [PubMed]

12.

Kesselheim AS, Franklin JM, Kim SC, Seeger JD, Solomon DH. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. J Gen Intern Med. 2015;30:1633–8. [DOI] [PubMed] [PMC]

13.

Robinson PC, Dalbeth N, Donovan P. Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol. Arthritis Care Res (Hoboken). 2021;73:1537–43. [DOI] [PubMed]

14.

Bevis M, Blagojevic-Bucknall M, Mallen C, Hider S, Roddy E. Comorbidity clusters in people with gout: an observational cohort study with linked medical record review. Rheumatology (Oxford). 2018;57:1358–63. [DOI] [PubMed]

15.

Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E, et al. Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. Am J Med. 2022;135:32–8. [DOI] [PubMed] [PMC]

16.

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381:2497–505. [DOI] [PubMed]

17.

Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al.; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383:1838–47. [DOI] [PubMed]

18.

Siddiqui MU, Junarta J, Sathyanarayanan S, Kochar K, Ullah W, Fischman DL. Risk of coronary artery disease in patients with gout on treatment with Colchicine: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2023;45:101191. [DOI] [PubMed] [PMC]

19.

Roddy E, Packham J, Obrenovic K, Rivett A, Ledingham JM. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. Rheumatology (Oxford). 2018;57:826–30. [DOI] [PubMed]

20.

Oderda GM, Shiozawa A, Walsh M, Hess K, Brixner DI, Feehan M, et al. Physician adherence to ACR gout treatment guidelines: perception versus practice. Postgrad Med. 2014;126:257–67. [DOI] [PubMed]

21.

Richette P, Flipo RN, Patrikos DK. Characteristics and management of gout patients in Europe: data from a large cohort of patients. Eur Rev Med Pharmacol Sci. 2015;19:630–9. [PubMed]

22.

Cottrell E, Crabtree V, Edwards JJ, Roddy E. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam Pract. 2013;14:170. [DOI] [PubMed] [PMC]

23.

Coleshill MJ, Day RO, Tam K, Kouhkamari M, Caillet V, Aung E, et al. Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. Br J Clin Pharmacol. 2022;88:4894–901. [DOI] [PubMed] [PMC]

24.

Schlesinger N, Etzel CJ, Greenberg J, Kremer J, Harrold LR. Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. J Rheumatol. 2016;43:924–30. [DOI] [PubMed]

25.

Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64:1447–61. [DOI] [PubMed] [PMC]

26.

Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al.; British Society for Rheumatology and British Health Professionals in Rheumatology Standards; Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46:1372–4. [DOI] [PubMed]

27.

Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22:28. [DOI] [PubMed] [PMC]

28.

Roddy E, Bajpai R, Forrester H, Partington RJ, Mallen CD, Clarson LE, et al. Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink. Ann Rheum Dis. 2023;82:1618–25. [DOI] [PubMed] [PMC]

29.

Bajpai R, Partington R, Muller S, Forrester H, Mallen CD, Clarson L, et al. Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study. Rheumatology (Oxford). 2024:keae229. [DOI] [PubMed]

30.

Rashid N, Levy GD, Wu YL, Zheng C, Koblick R, Cheetham TC. Patient and clinical characteristics associated with gout flares in an integrated healthcare system. Rheumatol Int. 2015;35:1799–807. [DOI] [PubMed] [PMC]

31.

Stamp LK, Horne A, Mihov B, Drake J, Haslett J, Chapman P, et al. Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy. Arthritis Care Res (Hoboken). 2024;76:1371–8. [DOI] [PubMed]

32.

Janssen CA, Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, van de Laar MAFJ. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare. Clin Rheumatol. 2019;38:2233–9. [DOI] [PubMed]

33.

Richardson JC, Liddle J, Mallen CD, Roddy E, Hider S, Prinjha S, et al. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout. BMC Musculoskelet Disord. 2016;17:249. [DOI] [PubMed] [PMC]

34.

Rebello C, Thomson M, Bassett-Clarke D, Martini N. Patient awareness, knowledge and use of colchicine: an exploratory qualitative study in the Counties Manukau region, Auckland, New Zealand. J Prim Health Care. 2016;8:140–8. [DOI] [PubMed]